Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/47482
Campo DC Valoridioma
dc.contributor.authorTiberi, Simonen_US
dc.contributor.authorScardigli, Annaen_US
dc.contributor.authorCentis, Rosellaen_US
dc.contributor.authorD'Ambrosio, Liaen_US
dc.contributor.authorMuñoz-Torrico, Marcelaen_US
dc.contributor.authorSalazar-Lezama, Miguel Ángelen_US
dc.contributor.authorSpanevello, Antonioen_US
dc.contributor.authorVisca, Dinaen_US
dc.contributor.authorZumla, Alimuddinen_US
dc.contributor.authorMigliori, Giovanni Battistaen_US
dc.contributor.authorCaminero Luna, Jose A.en_US
dc.date.accessioned2018-11-23T13:55:01Z-
dc.date.available2018-11-23T13:55:01Z-
dc.date.issued2017en_US
dc.identifier.issn1201-9712en_US
dc.identifier.urihttp://hdl.handle.net/10553/47482-
dc.description.abstractThe classification of anti-tuberculosis (TB) drugs is important as it helps the clinician to build an appropriate anti-TB regimen for multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB cases that do not fulfil the criteria for the shorter MDR-TB regimen. The World Health Organization (WHO) has recently approved a revision of the classification of new anti-TB drugs based on current evidence on each drug. In the previous WHO guidelines, the choice of drugs was based on efficacy and toxicity in a step-down manner, from group 1 first-line drugs and groups 2-5 second-line drugs, to group 5 drugs with potentially limited efficacy or limited clinical evidence. In the revised WHO classification, exclusively aimed at managing drug-resistant cases, medicines are again listed in hierarchical order from group A to group D. In parallel, a possible future classification is independently proposed. The aim of this viewpoint article is to describe the evolution in WHO TB classification (taking into account an independently proposed new classification) and recent changes in WHO guidance, while commenting on the differences between them. The latest evidence on the ex-group 5 drugs is also discussed.en_US
dc.languageengen_US
dc.relation.ispartofInternational Journal of Infectious Diseasesen_US
dc.sourceInternational Journal of Infectious Diseases[ISSN 1201-9712],v. 56, p. 181-184en_US
dc.subject32 Ciencias médicasen_US
dc.subject320508 Enfermedades pulmonaresen_US
dc.subject.otherAnti-TB drugsen_US
dc.subject.otherBedaquilineen_US
dc.subject.otherDelamaniden_US
dc.subject.otherFluoroquinolonesen_US
dc.subject.otherLinezoliden_US
dc.subject.otherMDR/XDR-TBen_US
dc.titleClassifying new anti-tuberculosis drugs: rationale and future perspectivesen_US
dc.typeinfo:eu-repo/semantics/articleen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.ijid.2016.10.026en_US
dc.identifier.scopus2-s2.0-85009982262-
dc.contributor.authorscopusid57202669936-
dc.contributor.authorscopusid6506357242-
dc.contributor.authorscopusid6506479049-
dc.contributor.authorscopusid56582629500-
dc.contributor.authorscopusid54403359400-
dc.contributor.authorscopusid6602880102-
dc.contributor.authorscopusid6603926482-
dc.contributor.authorscopusid24077390000-
dc.contributor.authorscopusid7006170723-
dc.contributor.authorscopusid7005608870-
dc.contributor.authorscopusid56635538800-
dc.description.lastpage184en_US
dc.description.firstpage181en_US
dc.relation.volume56en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.description.numberofpages4en_US
dc.utils.revisionen_US
dc.date.coverdateMarzo 2017en_US
dc.identifier.ulpgcen_US
dc.contributor.buulpgcBU-MEDen_US
dc.description.sjr1,514-
dc.description.jcr3,202-
dc.description.sjrqQ1-
dc.description.jcrqQ2-
dc.description.scieSCIE-
item.grantfulltextnone-
item.fulltextSin texto completo-
crisitem.author.deptGIR IUIBS: Patología médica-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.orcid0000-0002-2931-9483-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameCaminero Luna, José Antonio-
Colección:Artículos
Vista resumida

Citas SCOPUSTM   

80
actualizado el 24-mar-2024

Visitas

35
actualizado el 19-ago-2023

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.